Retour aux projets

18540.1 IP-LS

18540.1 IP-LS

Résumé

Engineered arrestins as novel biosensors for drug-induced GPCR phosphorylation

Textes supplémentaires

Abstract

Promising drug candidates entering pre- and clinical trials account for more than 50% of the total Pharma R&D|spending and have a failure rate of 95%. About half of them target GPCRs, an important superfamily of|membrane receptors. For better and earlier assessment of quality, safety, and effectiveness of drug|candidates, we will develop cellular screening systems on a unique arrestin-engineering platform to enable|high-throughput dissection of drug-induced GPCR signaling.

Participants

Maria Waldhoer

Wirtschaftspartner

waldhoer@interaxbiotech.com

InterAx Biotech AG Maria Waldhoer PARK innovAARE 5234 Villigen AG CH

Gebhard Schertler

Kontaktperson

gebhard.schertler@psi.ch

PSI Paul Scherrer Institut Gebhard Schertler 5232 Villigen AG CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2016-06-30
Date de fin
2019-11-30
Coûts totaux approuvés
CHF 493680.00
Section
60 Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%